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Introduction: Protein expression is deregulated in cancer, and the proteomic changes
observed in lung cancer may be a consequence of mutations in essential genes. The
purpose of this study was to identify protein expression associated with prognosis in lung
cancers stratified by smoking status, molecular subtypes, and EGFR-, TP53-, and KRAS-
mutations.
Methods: We performed profiling of 295 cancer-relevant phosphorylated and non-
phosphorylated proteins, using reverse phase protein arrays. Biopsies from 80 patients
with operable lung adenocarcinomas were analyzed for protein expression and
association with relapse free survival (RFS) were studied.
Results: Spearman’s rank correlation analysis identified 46 proteins with significant
association to RFS (p<0.05). High expression of protein kinase C (PKC)-a and the
phosporylated state of PKC-a, PKC-b, and PKC-d, showed the strongest positive
correlation to RFS, especially in the wild type samples. This was confirmed in gene
expression data from 172 samples. Based on protein expression, unsupervised
hierarchical clustering separated the samples into four subclusters enriched with the
molecular subtypes terminal respiratory unit (TRU), proximal proliferative (PP), and
proximal inflammatory (PI) (p=0.0001). Subcluster 2 contained a smaller cluster (2a)
enriched with samples of the subtype PP, low expression of the PKC isozymes, and
associated with poor RFS (p=0.003) compared to the other samples. Low expression of
the PKC isozymes in the subtype PP and a reduced relapse free survival was confirmed
with The Cancer Genome Atlas (TCGA) lung adenocarcinoma (LUAD) samples.November 2020 | Volume 10 | Article 5907551
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Frontiers in Oncology | www.frontiersin.orgConclusion: This study identified different proteins associated with RFS depending on
molecular subtype, smoking- and mutational-status, with PKC-a, PKC-b, and PKC-d
showing the strongest correlation.Keywords: non-small cell lung cancer, protein profiling, expression subtypes, protein kinase C, adenocarcinoma,
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Proteins are the functional players driving both normal and
disease processes. Some of the most important types of
mutations in lung cancer occur in epidermal growth factor
(EGFR), tumor protein p53 (TP53), and Kirsten rat sarcoma
viral oncogene homolog (KRAS). Mutations in these genes may
lead to changes in many interacting pathways, leading to
significantly altered protein expression. They are known to
influence treatment response and regarded as essential for
progression of lung cancer (1). Some of the changes in protein
expression observed in lung cancer are a consequence of
mutations in essential driver genes, and targeted therapy is
usually efficient for these subgroups of patients (2).
Patients with somatic genomic alterations in the EGFR gene
are routinely treated with EGFR inhibitors, which have improved
the outcome for this patient group (3). Mutations in KRAS leads
to constitutively and persistent stimulus-independent activation
of downstream pathways affecting tumor growth, proliferation,
and survival. Developing treatment targeting KRas has proved to
be complicated, but ongoing studies investigate inhibition of
effector-molecules downstream of KRas, including (extracellular
signal-regulated kinase) ERK and mitogen-activated extracellular
signal-regulated kinase (MEK) (4). Nevertheless, MEK inhibitors
are associated with early development of resistance due to
crosstalk with other signaling pathways which make this
approach challenging (5). So far, no efficient therapy to re-
establish the function of p53 is in clinical use, but studies with
reactivation of p53 have been performed (6). In order to improve
outcome for lung cancer patients, stratification based on
alterations in essential genes and the affected pathways may
lead to better treatment strategies and increased response rate.
To sub-classify non-small cell lung cancer (NSCLC), intrinsic
molecular subtypes have been explored based on gene expression
profiling. Three subtypes have been identified for the
adenocarcinomas, namely the bronchioid, magnoid, and
squamoid subtype, later re-named to terminal respiratory unit
(TRU), proximal proliferative (PP), and proximal inflammatory
(PI), respectively (7–9). The TRU subtype is most common
among females and never-smokers, and often includes tumorsma receptor tyrosine kinase; CIN,
mal growth factor receptor; ERK,
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with EGFRmutations and a less invasive phenotype. Early stages
of the TRU subtype imply better prognosis. Gene expression
profiles related to biological processes involved in excretion,
asthma, and surfactants are associated with the TRU subtype.
The PP subtype is reported with a high frequency of KRAS and
TP53 mutations, over-expression of DNA repair genes and is
often found in heavy smokers. The PI subtype is recognized with
over-expression of defense response genes such as CXCL10 and
is most common in high grade tumors (7). At late stages, the PI
subtype is associated with better survival compared to the other
subtypes (8). Chromosomal instability (CIN), copy number
alterations, and genomewide DNA methylations are also
reported to differ among the three subtypes, with the PP
subtype having the highest CIN (8). So far, protein expression
are reported to only partially correlate with the molecular
subtypes of adenocarcinoma (9). In order to treat lung cancer
patients more efficiently, groups of patients who share common
biological features such as mutations or pathway alterations
should be identified and treated with drugs optimized for their
subgroup. It has been known for a long time that never-smoking
NSCLCs are recognized with a different underlying biology
compared to ever-smokers. However, except from a handful of
known genetic aberrations such as EGFR mutations and
anaplastic lymphoma receptor tyrosine kinase (ALK)
rearrangement, no subgroups of NSCLC are stratified for
optimized treatment based on the molecular profile of the tumor.
The purpose of this study of lung adenocarcinoma, was to
identify differences in protein expression levels associated with
prognosis, stratified on EGFR, TP53 and KRAS mutations status,
and smoking status.METHODS
Patients diagnosed with operable NSCLC adenocarcinoma from
2006 to 2011, were included and analyzed for protein expression
(n=80) in the Oslo cohort. The patients underwent curatively
intended surgical resection at Rikshospitalet, Oslo University
Hospital, Norway. Tumor samples were snap frozen in liquid
nitrogen and stored at −80°C until protein extraction.
Pathological stage, mutation status and smoking status are
outlined in Table 1. All the samples were classified as
adenocarcinomas. Never-smokers are defined as those who
have smoked less than 100 cigarettes. Out of the 80 patients,
10 died from non-lung cancer related causes, and were excluded
from Spearman’s test. One sample did not have gene expression
data, and was excluded for correlation analysis between gene
expression and protein data.November 2020 | Volume 10 | Article 590755
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We have performed profiling of 295 cancer relevant proteins of
which 60 were in a phosphorylated state (Supplementary Table
S2 and Supplementary Material and Methods) on the Oslo
cohort, using the reverse phase protein array (RPPA) core facility
at MD Anderson Cancer Center (Houston, TX). RPPA data
(n=131 proteins) and phenotypes from the lung adenocarcinoma
(LUAD) cohort were extracted from The Cancer Genome Atlas
(TCGA) data generated by the TCGA Research Network: http://
cancergenome.nih.gov/. Samples with no expression subtype
assigned and without registered relapse free survival were
filtered out. The remaining 181 LUAD samples were utilized as
validation set. Time to relapse was extracted for survival analyses.
Of note, the median follow-up time for alive patients was 23.9
months for the LUAD cohort, compared to 60 months for the
Oslo cohort.
EGFR, TP53, and KRAS Analyses
Mutation analyses of EGFR exons 18–21 were performed using
the therascreen EGFR mutation kit (DxS, Manchester, UK)
designed to detect 28 specific mutations in the EGFR gene.
Assays were carried out according to the manufacturer’s
protocol and with the use of the Roche LightCycler 480 Real-
Time PCR System. Some of the results were previously published
by Helland et al. (10).
The TP53 gene was analyzed by the Sanger sequencing
method in all the tumor samples. The procedure was
performed on an Applied Biosystems 3730 DNA Analyzer
according to the supplier’s handbook, Applied Biosystem 3730/
3730X/DNA Analyzers Part 4331467 Rev.B, as previously
described (11). More details are provided in Supplementary
Material and Methods.
We used the wobble-enhanced ARMS (WE-ARMS) method
for detecting KRAS mutations in the lung adenocarcinoma
samples. This mutation assay detects the seven most
commonly reported mutations in the KRAS gene—KRAS
g.34G>C (p.G12R), g.34G>A (p.G12S), g.34G>T (p.G12C),
g.35G>A (p.G12D), g.35G>C (p.G12A), g.35G>T (p.G12V),
and g.38G>A (p.G13D)—by real-time PCR (12).Frontiers in Oncology | www.frontiersin.org 3Gene Expression and Subtyping of
Adenocarcinoma Samples
Gene expression was performed on 186 adenocarcinomas
(including 79 of those with protein expression) from the
same cohort, using hybridization arrays (SurePrint G3 Human,
8x60K, Agilent Technologies). More details are provided in
Supplementary Material and Methods. Clinical information
such as pathological stage, mutation status, and smoking status
are outlined in Supplementary Table S1. The adenocarcinoma
samples were assigned a gene expression subtype using the
previously described 506 gene centroid classifier and Pearson
correlation (7, 8). Four of the samples had a negative correlation
with all three subtypes and were not assigned to any subtype. Out
of the 186 samples with gene expression, 14 were excluded in the
Spearman’s test due to dead of other reasons than lung cancer.
The data are deposited at ArrayExpress with accession number:
E-MTAB-7954.
Immunohistochemistry
Immunohistochemistry (IHC) staining for the neuroendocrine
markers CD56, synaptophysin, chromogranin A, and NSE were
performed on a selected subset of 11 samples, using the
antibodies as outlined in Supplementary Table S3 and
Supplementary Material and Methods.Statistics
All the statistical analysis were performed in R (v 3.3.2) (13)
using RStudio (v 1.1.447). Hierarchical clustering was performed
to visualize the total protein expression for all the samples with
mutation status, stage, subtype, smoking history, and relapse free
survival (RFS) data included. Hierarchical clustering was
performed using the R-package Clustermap (Lingjærde et al.
personal communication). In brief, median-centered and log2-
transformed RPPA-data were clustered using Pearson distance
and average linkage, and with N=200 iterations in the PART
method used to estimate the number of clusters, as described
previously (14). For heatmap visualization of the data, values are
normalized to the range [−1.2, 1.2] by application of a non-linear
sigmoid transformation f(x) = 1.2*tanh(x/1.2). This limits the
visual dominance of outlier values while maintaining the order of
the values, since f is strictly increasing. RFS was calculated from
the date of surgery until the date of event, defined as local relapse,
metastases or death from lung cancer. Cut-off was set to 60
months. Correlation between protein expression/gene expression
and RFS was calculated using two-sided Spearman’s test. Due to
the restricted number of patients in this cohort, the p-value for
these analyses are unadjusted. The reproducibility was assessed
using bootstrapping method. Patients who died from other
causes than lung cancer were filtered out in the Spearman’s
test. Student t-test was performed to identify differentially
expressed proteins between the groups of interests. Survival
analysis was performed using cox regression analysis and
Kaplan Meyer survival plot. The significance threshold was set
to p<0.05. In order to reduce the false discovery rate, the p-value
was adjusted using the Benjamini-Hochberg procedure.TABLE 1 | Age, gender, adjuvant chemotherapy, mutation status, smoking
history, and stage are displayed for the patients analyzed for protein expression
(n=80).
Condition Number
Age Median (range) 67.2 (44.8–84.1)
Gender Female (male) 43 (37)
Adjuvant chemotherapy Chemo (no chemo) (nd) 21 (47) (12)
EGFR Mutated (WT) 9 (71)
KRAS Mutated (WT) (nd) 31 (48) (1)
TP53 Mutated (WT) 31 (49)




nd 2Number of samples not mutated, wild type (WT), are shown in brackets. No data, nd.November 2020 | Volume 10 | Article 590755
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We performed RPPA on biopsies from 80 lung adenocarcinoma
biopsies. The tumor samples were tested for mutations in the
EGFR-, TP53-, and KRAS genes, where 12.5% had EGFR
mutations, 39% had KRAS mutations and 39% had mutations
in the TP53 gene. In the group of patients with EGFR mutated
tumors, four (representing 44%) were never smokers (Table 1).
Out of 80 patients, 36 (45%) patients were registered with RFS >
60 months. Among these, three (8%) of the tumors were EGFR
mutated, 15 (42%) were TP53 mutated, 13 (36%) were KRAS
mutated and three patients were never smokers.
Hierarchical Clustering Analysis
Unsupervised hierarchical clustering analysis performed on
protein expression grouped the samples into four subclusters
as shown in the dendrogram (Figure 1). The parameters EGFR-,
TP53-, KRAS- mutations, stage, event, and smoking status were
evenly distributed between the sub-clusters (p> 0.05 in Fisher
exact test). The molecular subtypes were significantly associated
with the four subclusters (p = 0.0001), of which subcluster 1
(green branches) was mainly associated with the PI subtype,
subcluster 2 (red branches) enriched with the PP subtype, andFrontiers in Oncology | www.frontiersin.org 4subcluster 3 and 4 (turquoise and blue branches) were associated
with the TRU subtype. Subcluster 2 contained four smaller
clusters (2a, 2b, 2c, and 2d visualized in Supplementary
Figure S1) of which 2a (marked with red box beneath of the
branches in Figure 1 and Supplementary Figure S1) was
recognized with early relapse (median RFS = 9 months). We
used multivariate cox regression analysis, where the samples in
subcluster 2b, 2c, and 2d were analyzed as one group and stage
was included as a covariate in the model, confirming a
significantly shorter RFS for samples within subcluster 2a
compared to the other subclusters (p=0.003). This association
was visualized with a Kaplan Meier survival plot (Figure 2). The
heatmap further demonstrated that cluster 2a had very low
expression of several proteins recognized as members in the
MAPK pathway and mTOR pathway. In addition, protein kinase
C (PKC)-a and phosphorylated PKC-a- pS657, PKC-b-II-
pS660, and PKC-d- pS664 were significantly lower expressed in
subcluster 2a compared to the other samples (Wilcoxon rank
test, FDR <0.05, Supplementary Table S4). To identify the
proteins with the highest correlation to RFS within this group,
Spearman’s rank correlation was utilized (two samples reported
with non-lung cancer related death were excluded in this
analysis). Six proteins (myosin11, CD26, caspase 7 cleaved,FIGURE 1 | Unsupervised hierarchical cluster analysis based on protein expression from 80 non-small cell lung cancer (NSCLC) samples. Clinical variables such as
smoking status, mutations status of the gene TP53, KRAS, and EGFR, RFS (ranging from 1 month = light green to dark green = 60 months) and event, were
included to see if these features were enriched within the clusters. Events were divided into four categories; no event, relapse (which also includes metastasis), dead
of lung cancer and dead of other reasons. The samples clustered into four subclusters marked with green, red, turquoise, and blue branches. Beneath subcluster
two (red branch) a red box indicates a smaller cluster named 2a, and a pink box is drawn beneath subcluster 2b, 2c, and 2d. Subcluster 2a is recognized with poor
RFS and enriched with subtype PP. The proteins are clustered into nine subclusters seen on the left side. The proteins PKCa, PKCa_p, and PKCd_p belongs to the
yellow cluster, and PKCb-II_p is shown in the turquoise cluster.November 2020 | Volume 10 | Article 590755
Halvorsen et al. Protein Expression in NSCLCsYAP, ER, and 4E-BP1-pT37-T46) were significantly associated
(p< 0.05) with RFS in subcluster 2a (Supplementary Table S5).
To check if subcluster 2a contained neuroendocrine-like features,
the expression of the genes NCAM1, CHGA, SYP encoding for
the neuroendocrine markers CD56, chromogranin A, and
synaptophysin respectively, were analyzed. All three markers
revealed a higher gene expression in samples from subcluster 2a
compared to all the other samples, but only SYP was significant
(p=0.03). IHC staining for the proteins CD56, chromogranin A,
synaptophysin, and neuron-specific enolase (NSE) were
performed for the 11 samples in subcluster 2a, and confirmed
an positive expression of synaptophysin, CD56, chromogranin
A, and NSE in seven, one, one, and nine of the 11 samples,
respectively (Supplementary Table S6). Serum levels of the
neuroendocrine markers proGRP, chromoganin A, and NSE
were elevated in one of the 11 samples (data not shown).
Unsupervised hierarchical clustering of mRNA expression
data of the genes coding for the analyzed proteins (n=226) were
performed on a cohort of 186 adenocarcinoma samples,
including the 79 with RPPA data (Supplementary Figure S2).
The clustering confirmed a different gene expression pattern
for the three molecular subtypes (p = 1.3*E−16 in Fisher exact
test). The subtype PI was scattered between several subclusters,
but the majority of the TRU samples were found in the largest
subcluster, whereas most of the PP subtype samples clustered
together. Focusing on the 11 samples from subcluster 2a
identified using protein expression data, only the samples with
the PP subtype (n=7) clustered together with samples recognized
with poor RFS and PP subtype, when using mRNA data. Time to
progression, TP53 - and EGFR- mutation status were
significantly differentially distributed between the subclusters
(p < 0.05).Frontiers in Oncology | www.frontiersin.org 5Protein Expression Associated With
Prognosis
Using Spearman’s rank correlation, we identified 46 proteins
significantly associated with RFS (unadjusted p<0.05), of which
eight were in a phosphorylated state (Supplementary Table S5).
We used bootstrapping (n=1,000 bootstrapping samples) to
evaluate the standard deviation of the rho value; 45 of the 46
proteins reported with p-value <0.05 had rho-values within two
standard deviations, including all PKC proteins, confirming the
reproducibility of the test (Supplementary Table S7). High
expression of PKC-a, and phosphorylated PKC-a, PKC-bII,
and PKC-d were all highly associated with increased RFS as
outlined in Table 2 (p<0.05).
Spearman’s rank correlation performed pair-wise for 79
samples on the proteins and phosphorylated proteins, and the
corresponding gene expression data (Supplementary Figure S3,
Supplementary Table S8) revealed a positive correlation (>0.3)
for 110 of the proteins, and a negative correlation for 42 of
the proteins.
Next, we included the samples with mRNA data (n=172) and
performed a Spearman’s Rank correlation between genes and
proteins associated with prognosis, and found 13proteins/genes
significantly associated with RFS in both analysis (Table 3 and
Supplementary Figure S3).Protein Expression With Impact on
Prognosis Differ Depending on Mutational
and Smoking Status
A significant association between RFS and expression of 15
proteins (Supplementary Table S5), including MEK-1,
phosphorylated bad, collagen VI, LCA3B, and CD49b was seenFIGURE 2 | Kaplan Meier survival plot shows that subcluster 2a (red) had worse relapse free survival (RFS) compared to the other subclusters (p=0.003). The
different subclusters are generated from the hierarchical clustering in Figure 1. Subcluster 2b contains 2b, 2c, and 2d shown with pink color. The colors used for the
subclusters correspond to the color used for the subclusters in Figure 1. Number of samples in the different subclusters are: subcluster 1 n = 25, 2a: n=11, 2b/2c/
2d: n = 12, 3: n = 20, and 4: n=12.November 2020 | Volume 10 | Article 590755
Halvorsen et al. Protein Expression in NSCLCsin never smokers. Two proteins (LCA3B and Myosin 11) were
significantly associated with RFS in both never-smokers and
smokers (Supplementary Figure S4).
High expression of B7-H3 was associated with poor survival
in the total group, but only found to be significant in KRAS and
TP53 wild type tumors, smokers, and EGFR mutated samples
after stratification (p<0.05, Supplementary Table S5). Seven out
of the nine EGFR mutated samples showed B7-H3 expression
level above the average in the total group.
When comparing similarities in RFS-associated proteins
between the mutated samples and the wild type samples one,
three and four overlapping proteins were identified in the EGFR,
KRAS, and TP53 subgroups, respectively. The proteins PKC-a
and phosphorylated PKC-a, PKC-bII, and PKC-d were the most
significantly RFS-associated proteins in smokers, TP53wt,
EGFRwt, and KRASwt. Samples with EGFRmut, RFS wasFrontiers in Oncology | www.frontiersin.org 6significantly associated with PKC-d, where five out nine
samples showed expression level above average in the total
group. In samples with TP53mut or KRASmut, RFS was
significantly associated with PKC-a and phosphorylated PKC-
a. Among the mutated samples, fewer proteins were associated
with RFS, and as expected, no overlapping proteins were found
between EGFR and KRAS mutated samples (Supplementary
Table S5 and Supplementary Figure S4). The same analyses
were applied to the 172 samples with gene expression data, where
fewer genes were associated with RFS in samples harboring a
mutation compared to wild type samples. In the groups stratified
on mutational status and smoking status, the level of PRKCA,
encoding PKC-a, were significantly associated with RFS in
smokers, EGFR wt, KRAS wt, and TP53 mut samples. The level
of PRKCD, encoding PKC-d, was significantly associated with
RFS among smokers, EGFR wt, EGFR mut, KRAS wt, and
TP53 wt.
A tendency toward worse relapse free survival in patients with
low expression of PKC-d was also seen in the TCGA data
(p=0.06, Figure 3). The PP subtype showed a significantly
decreased expression of PKC-a, and phosphorylated PKC-a
and PKC-d when compared to PI and TRUE subtype. Further,
the PP subtype also showed a reduced relapse free survival when
compared to non-PP samples (p=0.085, Figure 3).DISCUSSION
In this study we examined the expression of 235 proteins and
60 phospho-proteins in tumors from 80 patients diagnosed
with lung adenocarcinomas. We identified 46 proteins and
phospho-proteins likely to impact the patient outcome. When
stratifying the samples according to mutations in the genes
TP53, EGFR, or KRAS, more proteins were associated with
RFS in samples without mutations. This was also seen when
analyzing the corresponding mRNA data. Cluster analysis
identified a small subcluster containing 11 patients enriched
with tumors of the PP subtype, recognized with early relapse,
low expression of PKC isozymes, and increased expression of
neuroendocrine markers.TABLE 3 | Intersection of messenger RNAs (mRNAs) and proteins significantly
correlated to relapse free survival (RFS).
















AR AR 0.475 0.172 0.241
CCNB1 Cyclin.B1 0.758 −0.256 −0.257
CCNE1 Cyclin.E1 0.682 −0.177 −0.254
DPP4 CD26 0.720 0.274 0.266
KIT c.Kit 0.815 −0.232 −0.253
LCK Lck 0.615 0.172 0.287
MIF MIF 0.549 −0.252 −0.346
PIK3R1 PI3K.p85 0.38 0.193 0.264
PRKCA PKC.a 0.648 0.208 0.356
PRKCD PKC.delta_pS664 0.18 0.225 0.348
RPS6KA1 RSK 0.543 0.244 0.272
SLC1A5 SLC1A5 0.520 −0.184 −0.263
STAT5A Stat5a 0.462 0.228 0.265The pair-wise Spearman’s rank correlation mRNA/protein was performed on 79 samples.
Only significantly positively pairwise correlations and mRNA/proteins simultaneously
significantly correlated to RFS are included in the list. In the RFS analysis, patients
reported with non-lung cancer related death were filtered out.TABLE 2 | Top 10 proteins correlated with RFS (Spearman’s rank correlation, p<0.05).
Protein Rho p-value Adjusted p-value rho.sd 2.sd rho>2*SD
c.Abl −0.422 <0.001 0.081 0.102 0.204 Yes
PKC.b.II_pS660 0.376 0.001 0.141 0.11 0.22 Yes
PAI.1 −0.372 0.002 0.141 0.107 0.214 Yes
PKC.a 0.356 0.002 0.141 0.107 0.214 Yes
MIF −0.346 0.003 0.141 0.11 0.22 Yes
PKC.a_pS657 0.35 0.003 0.141 0.108 0.216 Yes
PKC.delta_pS664 0.348 0.003 0.141 0.119 0.238 Yes
LC3A.B −0.338 0.004 0.155 0.12 0.24 Yes
Caveolin.1 0.323 0.006 0.165 0.109 0.218 Yes
GPBB 0.323 0.006 0.165 0.121 0.242 YesNovember 2020 | Volume 10 | ArtiThe total list of the 46 identified proteins from this analysis including adjusted p-value (Benjamini-Hochberg) is displayed in Supplementary Table S7.
The correlation coefficient shows the strength and direction between the two variables RFS and protein expression, and bootstrapping was utilized to evaluate the standard deviation of the
rho value.cle 590755
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Based on the expression of 295 proteins, unsupervised
hierarchical clustering separated the samples into four
subclusters. However, pathological stage, smoking status, or
mutations in the genes TP53, KRAS or EGFR did not seem to
impact the clustering. Interestingly, the four subclusters were
significantly correlated with the molecular subtypes TRU, PP,Frontiers in Oncology | www.frontiersin.org 7and PI. Previous work using protein expression identified six
subgroups of adenocarcinoma, where the subgroups partially
overlapped with the three mRNA-derived subtypes. The PP
subtype was further divided into two groups (9), which also
was seen in our data set. Subcluster 2a, enriched with PP subtype
samples, was recognized with lower expression of members of
the mTOR pathway and the MAPK pathway. This is in line withA
C D E
B
FIGURE 3 | (A) Kaplan Meyer survival plot demonstrate reduced relapse free survival in patients with PP subtype (p = 0.085). (B) Kaplan Meyer survival plot shows that
low levels of phosphorylated PKCd (p= 0.0683, log rank test) are associated with reduced relapse free survival. The molecular subtypes terminal respiratory unit (TRU),
proximal inflammatory (PI), and proximal proliferative (PP) display different levels of (C) phosphorylated PKCd, (D) phosphorylated PKCa, and (E) PKCa. The lowest level
is seen in the PP samples for all three proteins. These results are calculated from lung adenocarcinoma (LUAD) samples in The Cancer Genome Atlas (TCGA).November 2020 | Volume 10 | Article 590755
Halvorsen et al. Protein Expression in NSCLCsprevious finding where TRU samples are associated with higher
expression of these proteins when compared to PP samples (15).
Interestingly, cluster analysis performed on mRNAs
corresponding to the proteins, grouped the samples with PP
subtype from the protein-derived subcluster 2a together, but not
the non-PP subtypes. However, the distinct pattern with very low
expressed proteins within subcluster 2a, was not reflected using
mRNA data. This can be explained with a lower correlation
between phosphorylated proteins and the corresponding genes.
Seven of the 11 samples within subcluster 2a showed a positive
staining for synaptophysin which are considered as a
neuroendocrine marker and can be used to confirm the
diagnosis (16). In total, 10 of the 11 samples showed positive
staining for at least one of the neuroendocrine marker or NSE.
According to WHO 2015, about 10–20% of lung tumors lacking
neuroendocrine morphology by light microscopy may reveal
neuroendocrine differentiation using IHC (17). In a recent
study on NSCLCs, a molecular subgroup enriched with PP
subtype and shorter survival was identified. These samples had
a mixed histology predominantly with adenocarcinomas with
molecular expression pattern associated with neuroendocrine
tumors (15). LCNEC (large cell neuroendocrine carcinoma) can
share some of the same pathological features as adenocarcinomas,
and LCNEC with areas of adenomatous differentiations (mixed
LCNEC) is described. Both pure LCNEC and mixed LCNEC
tumors exhibit an aggressive behavior and are associated with
poor survival (18) as seen within subcluster 2a in our analyses.
The hierarchical clustering performed on 186 mRNA samples
resulted in a significantly different distribution of the molecular
subtypes between the clusters, although the PI samples did not
cluster together. Of note, the overlap between the genes used for
the original sub-typing (8) and our clustering based on protein
expression was sparse (n=18), indicating that the proteins
included in our analysis seem to be important for the subtypes.
Both the TRU- and PP-subtype clustered based on our mRNA
data, and we suggest that the TRU- and PP-subtypes are more
distinct subtypes compared to PI. In a large meta-study, the TRU
subtype was identified as the most prognostically important
subtype compared to the non-TRU subtype, arguing for the
need to identify additional classifiers (19).
Protein Kinase C Levels Associated With
Survival
The protein kinase C is a group of enzymes known to be involved in
diverse cellular functions, including cell proliferation, apoptosis,
and cell migration, and has been regarded as an onco-protein. The
members of the PKC-family are encoded from nine different genes
which have several known splice variants. Recent work has
demonstrated that these proteins may have a more complex role
than first assumed, which is supported by the many failed clinical
trials for cancer using PKC-inhibitors. In addition, mutational
studies have revealed that most cancers have loss of function
(LOF) mutations in genes belonging to the PKC-family,
suggesting a tumor suppressor role for the proteins (20, 21). A
meta-study on the use of PKC-inhibitors combined with
chemotherapy in lung cancer patients reported decreasedFrontiers in Oncology | www.frontiersin.org 8response rate and disease control, compared to chemotherapy
alone (22). In our study, low expression of PKC-a, and
phosphorylated PKC-a, PKC-bII, and PKC-d were associated
with poor RFS. In addition, the levels of the PKC isozymes were
strikingly lower in subcluster 2a which also contained the samples
with the overall poorest RFS. An association with low expression of
PKC- d and decreased relapse free survival was confirmed in the
LUAD TCGA samples. Low levels of PKC-a, and phosphorylated
PKC-a and PKC-d in subtype PP were also found in the TCGA
samples. This support the findings in the Oslo cohort, with poor
RFS and low expression of the isozymes of PKC in subgroup 2a
containing mainly PP samples. Unfortunately, sparse information
on mutational status, reduced number of proteins analyzed, short
follow-up time, limited further validation on the TCGA samples.
Thus, with regard to the classical role of the PKC-family, our
results suggest a general tendency toward a tumor suppressor
role for PKC-a, PKC-bII, and PKC-d in NSCLC.
In theEGFRmutated samples,PKC-d levelspositively correlated
to patient survival. It has been reported that an activation of PKC-d
can be promoted by an activated EGFR (23). Further, activation of
PKC-dmay induceapoptosis andgrowtharrest resulting in reduced
tumorigenesis (24). As a response to DNA damage, it has been
shown that over-expression of p53 increases the transcription of
PKC-d resulting in apoptosis. This may explain the significant
correlationwe discovered between the protein expression of PKC-d
and RFS in TP53 wild type samples, but not in the TP53 mutated
samples.Nevertheless, thiswasnot reflectedby themRNAanalyses.
It’s been demonstrated that PKC can phosphorylate many
oncoproteins to suppress their activity, including KRas, PI3K, and
several tyrosine kinase receptors (25). The oncoprotein KRas,
recognized with activating mutations in cancer, can be suppressed
by activated PKC, which is proposed as a novel approach to target
KRas (26). A negative correlation between KRas and PKC-a was
recently described in colorectal cancer. Further, low expression of
PKC-a was also associated with poor prognosis (27). This is in
concordance with our results, where high levels of both PKC-a and
PKC-dwas associatedwithbetterRFS. The level of PKC-d showed a
higher correlation to RFS in those withKRASwild type, which also
were confirmedwhenusingmRNAdata. Interestingly, no isozymes
of PKCdid influence on survival in never-smoking patients, further
supporting this group as a distinct lung cancer disease driven by
other mechanisms.
This leads to the hypothesis that PKC may also have an
essential role keeping oncoproteins in check (25). Based on our
results, we suggest that the association to RFS for the different
PKC- isozymes is connected to mutational and smoking status.
Results from gene expression analysis performed on 172 NSCLC
samples strengthen these observations. Limitation to this study is
the small number of samples included in the protein analysis,
and the lack of a proper validation material. Due to the restricted
number of patients in this cohort, the p-value for Spearman’s
rank correlations analyses are unadjusted. However, we included
the bootstrapping method, which confirmed the reproducibility
of our results. More analyses are warranted in order to confirm
our findings. Unfortunately, we have not found similar RPPA
studies in lung cancer tissue for comparison with our results.November 2020 | Volume 10 | Article 590755
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Lung Cancer
Interestingly, high expression of B7-H3, a molecule involved in
immune checkpoint signaling, was correlated to poor outcome in
our study, especially in smokers, those without any detected
mutations in KRAS or TP53, and in those harboring an EGFR
mutation. B7-H3 is a molecule known to inhibit T-cell activation in
an immune suppressive manner. This protein has been shown to be
linked to poor survival in cancer, and have been suggested as a new
immune checkpoint target (28). In a recent study of lung cancer
patients, expression of B7-H3 was associated with overall survival
only in smokers (29). This indicates that future anti-B7-H3 therapy
may have higher success rate among ever smoking lung cancer
patients withKRAS orTP53wild type tumors, or anEGFRmutation.
Within subcluster 2a, six proteins were significantly associated
with RFS, where low expression of myosin II showed the highest
correlationwithbetterRFS.This is also supportedbyaprotein study
on early stage lung cancer where myosin IIa was reported to be
upregulated in stage Ia/Ib lung cancer patients with early relapse
(30). Interestingly, low expression of YAP was significantly
associated with increased RFS in subcluster 2a. Further, a
tendency toward better RFS was associated with low expression of
phosphorylatedYAP (p=0.1) and phosphorylatedHSP27 (p=0.12).
It has been shown that high expression of HSP27 leads to less
phosphorylated YAP (s127). Further, phosphorylation of YAP on
S127 decreased the activity of YAP since this prevent its
translocation to the nucleus (31). This also means that un-
phosphorylated YAP promotes tumor aggressiveness and is
related to poor prognosis which is in line with our study. These
finding highlight the central role HSP27 has in several pathways,
including the Hippo pathway.
Correlation Analysis Between Messenger
RNA and Protein Expression
Spearman’s Rank correlation revealed a high correlation (rho
>0.3) between expression levels of almost half of the proteins and
mRNAs. Previous studies have reported that much of the
variation in mean-level protein expression can be explained by
variation in mRNA expression (32, 33). However, the variance in
the proteomes across different tissue types can poorly be
explained by the mRNA levels, highlighting a tissue-specific
posttranscriptional regulation of gene expression. In a study of
lung cancer, proteins involved in metabolic and translational
pathways were highly correlated with mRNA expression,
whereas proteins involved in extracellular matrix and adhesion,
were not correlated or anti-correlated (33). In a study of breast
cancer, 35% of the proteins correlated significantly (rho > 0.3)
with mRNA expression. The proteins, cyclin B1, cyclin E1, 4E-
BP1, PKC-a, and RAB 25 were highly correlated with mRNA
expression in breast cancer (34). This is in line with our study,
where these proteins showed a high correlation value (rho > 0.6).
Interestingly, HER2 was highly correlated in the breast cancer
study across all subtypes, but this protein was poorly correlated
with mRNA expression in our lung study (rho =0.17). On the
other hand, EGFR revealed rho=0.72 in our study, while in breastFrontiers in Oncology | www.frontiersin.org 9cancer a correlation between rho=0.15–0.3 was found. This
indicates that genes known to be deregulated in a specific
cancer type may be regulated by other mechanisms. Proteins
such as p53, CDKN1B, andMAPK14 showed very low correlation
with the mRNA expression both in our study on lung cancer and
in the breast cancer study (34). Lack of correlation between the
level of proteins and mRNAs measured in the cells can have
several explanations including copy number aberrations, miRNA
expression, and methylation.CONCLUSION
These results demonstrate that essential mutations in lung
carcinomas affect several proteins associated with outcome. Based
on our results, expression of PKCa and phosphorylated PKCa,
PKCb, and PKCd seem to be positively associated with RFS, with
different isozymes linked to smoking and mutational status of
EGFR, KRAS, and TP53. These results illustrate the need to better
understand the biological context in order to further improve
targeted therapy in cancer. This study supports that a therapy
restoring the level of specific isozymes of PKC activity may be
beneficial for subgroups of lung cancer patients basedon the genetic
background. However, further studies exploring these findings are
needed. We identified a subgroup of samples enriched with the
molecular subtype PP, recognized with early relapse, increased
expression of neuroendocrine markers, and a distinct protein
expression pattern, including low levels of PKC isozymes. These
patients may benefit from a more aggressive treatment regimen.
Proteins associated with RFS among never smokers were strikingly
different compared to the other investigated subgroups. This is not
surprising, but underscores the need for amore stratified therapy in
order to improve clinical outcome.DATA AVAILABILITY STATEMENT
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